Current Report Filing (8-k)
August 21 2015 - 8:52AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 21, 2015
QLT Inc.
(Exact Name of Registrant as specified in its charter)
British Columbia, Canada |
|
000-17082 |
|
N/A |
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
887 Great Northern Way, Suite 250, Vancouver, B.C.
Canada, V5T 4T5
(Address of principal executive offices)
Registrants telephone number, including area code: (604) 707-7000
Not Applicable
(Registrants name or former address, if change since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
x Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
As previously reported, on June 8, 2015, QLT Inc. (QLT or the Company) entered into an Agreement and Plan of Merger (the Merger Agreement) among QLT, InSite Vision Incorporated, a Delaware corporation (InSite Vision) and Isotope Acquisition Corp., a Delaware corporation and a wholly-owned subsidiary of QLT (AcquireCo). The Merger Agreement provides for a business combination whereby AcquireCo will be merged with and into InSite Vision (the Merger). As a result of the Merger, the separate corporate existence of AcquireCo will cease and InSite Vision will continue as the surviving corporation and an indirect wholly owned subsidiary of the Company.
On August 21, 2015, QLT issued a press release announcing that it has been advised by InSite Vision that the InSite Vision board of directors has determined that a previously announced unsolicited offer from a multi-national pharmaceutical company (the Bidder) to acquire all of the issued and outstanding shares of InSite Vision (the Proposal) constitutes a Company Superior Proposal (as defined in the Merger Agreement) and that InSite intends, subject to QLTs right to match the Proposal, to terminate the Merger Agreement and enter into an agreement with the Bidder to implement the Proposal. Under the Merger Agreement, QLT has the option until 5:00 p.m. PDT on Wednesday, August 26, 2015, to negotiate a possible amendment to the terms of the Merger Agreement to match or exceed the Proposal. QLT is considering its position with respect to the Proposal and its matching right, and will keep the market apprised of further developments.
The press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Number |
|
Description |
99.1 |
|
Press Release dated August 21, 2015 |
Important Information For Investors And Stockholders
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. In connection with the transactions referred to in this material, the Company has filed a registration statement on Form S-4 with the SEC containing a proxy statement of InSite Vision that also constitutes a preliminary prospectus of the Company. After the registration statement is declared effective InSite Vision will mail a definitive proxy statement/prospectus to stockholders of InSite Vision. This material is not a substitute for the proxy statement/prospectus or registration statement or for any other document that the Company or InSite Vision may file with the SEC and send to the Companys and/or InSite Visions stockholders in connection with the proposed transactions. INVESTORS AND SECURITY HOLDERS OF QLT AND INSITE VISION ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the proxy statement/prospectus (when available) and other documents filed with the SEC by the Company or InSite Vision through the website maintained by the SEC at http://www.sec.gov and, in the Companys case, also on the System for Electronic Document Analysis Retrieval (SEDAR) website maintained by the Canadian Securities Administrators at www.sedar.com. QLT shareholders may also obtain these documents, free of charge, from the Companys website at www.qltinc.com under the heading Investors and then under the heading Proxy Circulars or upon request directly to the Company to the attention of QLT Investor Relations, 887 Great Northern Way, Suite 250, Vancouver, British Columbia, Canada, V5T 4T5. Copies of the documents filed with the SEC by InSite Vision are available free of charge on InSite Visions website at www.InSiteVision.com or by contacting InSite Vision at 510-747-1220.
QLT and InSite Vision and certain of their respective directors and certain of their respective executive officers may be considered participants in the solicitation of proxies with respect to the proposed transactions under the rules of the SEC. Information about the directors and executive officers of QLT is set forth in its Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the SEC on February 26, 2015. Information about the directors and executive officers of InSite Vision is set forth in its Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the SEC on February 18, 2015. These documents can be obtained free of charge from the sources indicated above. Additional information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, have been included in the proxy statement and other relevant materials filed with the SEC.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
QLT INC. |
|
|
|
|
By: |
/s/ Geoffrey Cox |
|
Name: |
Geoffrey Cox |
|
Title: |
Interim Chief Executive Officer |
|
Date: August 21, 2015
3
Exhibit 99.1
News release
QLT PROVIDES UPDATE ON ITS PROPOSED ACQUISITION OF INSITE VISION INCORPORATED
For Immediate Release |
August 21, 2015 |
VANCOUVER, CANADA QLT Inc. (NASDAQ: QLTI; TSX: QLT) (QLT or the Company) announces that it has been advised by InSite Vision Incorporated (InSite) that the board of directors of InSite has determined in good faith after consultation with its independent financial and legal advisors that the previously announced unsolicited offer from a multi-national pharmaceutical company (the Bidder) to acquire all of the issued and outstanding shares of InSite (the Proposal) constitutes a Company Superior Proposal as defined in the Agreement and Plan of Merger, dated June 8, 2015, by and among Insite, QLT and Isotope Acquisition Corp., as amended and restated (the Merger Agreement). InSite has further advised QLT that InSite intends, subject to QLTs right to match the Proposal, to terminate the Merger Agreement and enter into an agreement with the Bidder to implement the Proposal.
Under the Merger Agreement, QLT has the option until 5:00 p.m. PDT on Wednesday, August 26, 2015 (the Negotiation Period), to negotiate a possible amendment to the terms of the Merger Agreement to match or exceed the Proposal. InSite has advised QLT that it intends to negotiate in good faith with QLT during the Negotiation Period. If at the end of the Negotiation Period such amended QLT proposal results in the Proposal not being a Company Superior Proposal under the Merger Agreement, InSite and QLT will enter into an agreement to reflect the amended terms of the transaction. In the event that QLT elects not to match or exceed the Proposal and if InSite terminates the Merger Agreement in order to enter into an agreement with the Bidder, then InSite is required to pay a termination fee to QLT in the amount of $1,170,000.
QLT is considering its position with respect to the Proposal and its matching right, and will keep the market apprised of further developments.
About QLT
QLT is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. We are focused on developing our synthetic retinoid program for the treatment of certain inherited retinal diseases.
QLTs head office is based in Vancouver, Canada and the Company is publicly traded on NASDAQ Stock Market (symbol: QLTI) and the Toronto Stock Exchange (symbol: QLT). For more information about the Companys products and developments, please visit our web site at www.qltinc.com.
Important Information For Investors And Stockholders
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. In connection with the transactions referred to in this material, the Company has filed a registration statement on Form S-4 with the SEC containing a proxy statement of InSite that also constitutes a preliminary prospectus of the Company. After the registration statement is declared effective InSite will mail a definitive proxy statement/prospectus to stockholders of InSite. This material is not a substitute for the proxy statement/prospectus or registration statement or for any other document that the Company or InSite may file with the SEC and send to the Companys and/or InSites stockholders in connection with the proposed transactions. INVESTORS AND SECURITY HOLDERS OF QLT AND INSITE ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the proxy statement/prospectus (when available) and other documents filed with the SEC by the Company or InSite through the
website maintained by the SEC at http://www.sec.gov and, in the Companys case, also on the System for Electronic Document Analysis Retrieval (SEDAR) website maintained by the Canadian Securities Administrators at www.sedar.com. QLT shareholders may also obtain these documents, free of charge, from the Companys website at www.qltinc.com under the heading Investors and then under the heading Proxy Circulars or upon request directly to the Company to the attention of QLT Investor Relations, 887 Great Northern Way, Suite 250, Vancouver, British Columbia, Canada, V5T 4T5. Copies of the documents filed with the SEC by InSite Vision are available free of charge on InSite Visions website at www.InSiteVision.com or by contacting InSite at 510-747-1220.
QLT and InSite and certain of their respective directors and certain of their respective executive officers may be considered participants in the solicitation of proxies with respect to the proposed transactions under the rules of the SEC. Information about the directors and executive officers of QLT is set forth in its Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the SEC on February 26, 2015. Information about the directors and executive officers of InSite Vision is set forth in its Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the SEC on February 18, 2015. These documents can be obtained free of charge from the sources indicated above. Additional information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, have been included in the proxy statement and other relevant materials filed with the SEC.
QLT Inc. Contacts:
For Investors:
Andrea Rabney or David Pitts
Argot Partners
P: 212-600-1902
andrea@argotpartners.com
david@argotpartners.com
For Media:
Chuck Burgess or Mike Pascale
Abernathy MacGregor
P:212-371-5999
clb@abmac.com
mmp@abmac.com
2
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Sep 2023 to Sep 2024